{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:53:22Z","timestamp":1774281202204,"version":"3.50.1"},"reference-count":78,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Locally advanced non-small cell lung cancer, especially mediastinal lymph node metastasis-positive stage IIIA-N2 cancer, is a heterogeneous disease state characterized by anatomically locally advanced disease with latent micrometastases. Thus, surgical resection or radiotherapy alone has historically failed to cure this disease. During the last three decades, persistent efforts have been made to develop a suitable treatment modality to overcome these problems using chemotherapy and\/or radiotherapy with surgical resection. However, the role of surgical resection remains unclear, and the standard treatment for stage IIIA-N2 disease is concurrent chemoradiotherapy. In general, adjuvant chemotherapy is indicated for completely resected pathological stage IB disease or lymph node metastasis-positive pathological stage II or IIIA disease. Platinum-based doublet cytotoxic chemotherapy is currently the standard regimen. Additionally, post-operative radiotherapy might be indicated for post-operatively proven mediastinal lymph node metastasis; i.e. clinical N0\u20131 and pathological N2 disease. With the remarkable progression that has recently been made in the field of chemotherapy, such as advances in molecular targeting agents and immune checkpoint inhibitors, the basic policy of chemotherapy has been shifting to personalized treatment based on the individual patient\u2019s oncogene driver mutation status, immune status and other parameters. The same trend is being seen in the treatment of stage IIIA-N2 disease. We should consider the past and upcoming results of several clinical trials to optimize the coming era of personalized treatment.<\/jats:p>","DOI":"10.1093\/jjco\/hyaa249","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T13:22:36Z","timestamp":1606310556000},"page":"333-344","source":"Crossref","is-referenced-by-count":7,"title":["Surgical challenges in multimodal treatment of N2-stage IIIA non-small cell lung cancer"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5601-4749","authenticated-orcid":false,"given":"Masafumi","family":"Yamaguchi","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of General Thoracic Surgery, Juntendo University Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Takamochi","sequence":"additional","affiliation":[{"name":"Department of General Thoracic Surgery, Juntendo University Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Kanagawa Cancer Center, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiro","family":"Okami","sequence":"additional","affiliation":[{"name":"Department of General Thoracic Surgery, Osaka International Cancer Institute, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiju","family":"Aokage","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Shiono","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshige","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Niigata Cancer Center Hospital, Niigata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8836-1027","authenticated-orcid":false,"given":"Yasuhiro","family":"Tsutani","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morihito","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-ichi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Lung Cancer Surgical Study Group (LCSSG) of the Japan Clinical Oncology Group (JCOG)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"key":"2021030800244033300_ref1","doi-asserted-by":"crossref","first-page":"29S","DOI":"10.1378\/chest.07-1347","article-title":"Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)","volume":"132","author":"Alberg","year":"2007","journal-title":"Chest"},{"key":"2021030800244033300_ref2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2021030800244033300_ref3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.resinv.2014.04.002","article-title":"Prognosis of lung cancer patients in Japan according to data from the Japanese Joint Committee of Lung Cancer Registry","volume":"52","author":"Sawabata","year":"2014","journal-title":"Respir Investig"},{"key":"2021030800244033300_ref4","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archinte.168.14.1541","article-title":"Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited","volume":"168","author":"Chee","year":"2008","journal-title":"Arch Intern Med"},{"key":"2021030800244033300_ref5","doi-asserted-by":"crossref","first-page":"e314S","DOI":"10.1378\/chest.12-2360","article-title":"Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Ramnath","year":"2013","journal-title":"Chest"},{"key":"2021030800244033300_ref6","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1148\/90.4.688","article-title":"The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo","volume":"90","author":"Roswit","year":"1968","journal-title":"Radiology"},{"key":"2021030800244033300_ref7","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJM199010043231403","article-title":"A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer","volume":"323","author":"Dillman","year":"1990","journal-title":"N Engl J Med"},{"key":"2021030800244033300_ref8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1378\/chest.117.2.358","article-title":"Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: radiation therapy oncology group, eastern cooperative oncology group, and southwest oncology group","volume":"117","author":"Sause","year":"2000","journal-title":"Chest"},{"key":"2021030800244033300_ref9","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.1999.17.9.2692","article-title":"Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer","volume":"17","author":"Furuse","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021030800244033300_ref10","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1200\/JCO.2005.03.070","article-title":"Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 study","volume":"23","author":"Fournel","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021030800244033300_ref11","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2021030800244033300_ref12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"2021030800244033300_ref13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021030800244033300_ref14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021030800244033300_ref15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"2021030800244033300_ref16","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S1470-2045(13)70142-6","article-title":"CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study","volume":"14","author":"Seto","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021030800244033300_ref17","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"2021030800244033300_ref18","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"2021030800244033300_ref19","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2021030800244033300_ref20","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"2021030800244033300_ref21","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/0003-4975(92)90373-C","article-title":"Randomized trial of neoadjuvant therapy for lung cancer: interim analysis","volume":"53","author":"Pass","year":"1992","journal-title":"Ann Thorac Surg"},{"key":"2021030800244033300_ref22","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/jnci\/86.9.673","article-title":"A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer","volume":"86","author":"Roth","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"2021030800244033300_ref23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199401203300301","article-title":"A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer","volume":"330","author":"Rosell","year":"1994","journal-title":"N Engl J Med"},{"key":"2021030800244033300_ref24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1067\/mtc.2003.15","article-title":"A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209)","volume":"125","author":"Nagai","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2021030800244033300_ref25","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(08)70156-6","article-title":"Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer","volume":"9","author":"Thomas","year":"2008","journal-title":"Lancet Oncol"},{"key":"2021030800244033300_ref26","doi-asserted-by":"crossref","first-page":"225S","DOI":"10.1378\/chest.89.4_Supplement.225S","article-title":"A new international staging system for lung cancer","volume":"89","author":"Mountain","year":"1986","journal-title":"Chest"},{"key":"2021030800244033300_ref27","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1002\/cncr.26689","article-title":"A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903)","volume":"118","author":"Katakami","year":"2012","journal-title":"Cancer"},{"key":"2021030800244033300_ref28","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(15)60294-X","article-title":"Induction chemoradiation in stage IIIA\/N2 non-small-cell lung cancer: a phase 3 randomised trial","volume":"386","author":"Pless","year":"2015","journal-title":"Lancet"},{"key":"2021030800244033300_ref29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0360-3016(02)02943-7","article-title":"Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group","volume":"54","author":"Johnstone","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021030800244033300_ref30","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jnci\/djk093","article-title":"Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer","volume":"99","author":"Meerbeeck","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2021030800244033300_ref31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet"},{"key":"2021030800244033300_ref32","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1200\/JCO.2015.62.6812","article-title":"Phase III study of surgery versus definitive concurrent Chemoradiotherapy boost in patients with Resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE)","volume":"33","author":"Eberhardt","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021030800244033300_ref33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0022-5223(19)33714-6","article-title":"Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. Results of a randomized prospective study. The Japan Clinical Oncology Group","volume":"106","author":"Ohta","year":"1993","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2021030800244033300_ref34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.lungcan.2003.08.028","article-title":"A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304)","volume":"43","author":"Tada","year":"2004","journal-title":"Lung Cancer"},{"key":"2021030800244033300_ref35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials","volume":"311","author":"Non-small Cell Lung Cancer Collaborative Group","year":"1995","journal-title":"BMJ"},{"key":"2021030800244033300_ref36","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa032792","article-title":"A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung","volume":"350","author":"Kato","year":"2004","journal-title":"N Engl J Med"},{"key":"2021030800244033300_ref37","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1200\/JCO.2005.09.017","article-title":"Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer","volume":"23","author":"Hamada","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021030800244033300_ref38","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/jnci\/djg059","article-title":"Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer","volume":"95","author":"Scagliotti","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2021030800244033300_ref39","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(06)70804-X","article-title":"Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (adjuvant Navelbine international Trialist association [ANITA]): a randomised controlled trial","volume":"7","author":"Douillard","year":"2006","journal-title":"Lancet Oncol"},{"key":"2021030800244033300_ref40","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa031644","article-title":"Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer","volume":"350","author":"Arriagada","year":"2004","journal-title":"N Engl J Med"},{"key":"2021030800244033300_ref41","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021030800244033300_ref42","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(10)60059-1","article-title":"Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data","volume":"375","author":"Arriagada","year":"2010","journal-title":"Lancet"},{"key":"2021030800244033300_ref43","volume-title":"Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer"},{"key":"2021030800244033300_ref44","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/S1470-2045(17)30691-5","article-title":"Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial","volume":"18","author":"Wakelee","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021030800244033300_ref45","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1200\/JCO.19.02674","article-title":"Randomized Phase III study of Pemetrexed plus cisplatin versus Vinorelbine plus cisplatin for completely resected stage II to IIIA nonsquamous non-small-cell lung cancer","volume":"38","author":"Kenmotsu","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021030800244033300_ref46","doi-asserted-by":"crossref","first-page":"9006","DOI":"10.1200\/JCO.2020.38.15_suppl.9006","article-title":"Randomized phase III study of irinotecan\/cisplatin (IP) versus etoposide\/cisplatin (EP) for completely resected high-grade neuroendocrine carcinoma (HGNEC) of the lung: JCOG1205\/1206","volume":"38","author":"Hirotsugu Kenmotsu","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021030800244033300_ref47","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1200\/JCO.2013.51.1816","article-title":"Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study","volume":"31","author":"Goss","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021030800244033300_ref48","volume-title":"A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)"},{"key":"2021030800244033300_ref49","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2007.14.4824","article-title":"Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023","volume":"26","author":"Kelly","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021030800244033300_ref50","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","article-title":"Adjuvant Erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, Phase III trial","volume":"33","author":"Kelly","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021030800244033300_ref51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021030800244033300_ref52","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"2021030800244033300_ref53","article-title":"Osimertinib as adjuvant therapy in patients (pts) with stage IB\u2013IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA","volume":"38","author":"Roy","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021030800244033300_ref54","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021030800244033300_ref55","volume-title":"A randomized phase III trial of adjuvant gefitinib versus cisplatin and vinorelbine in completely resected (stage II-III) non-small cell lung cancer (NSCLC) patients with mutated EGFR (investigator-initiated multicenter clinical trial)"},{"key":"2021030800244033300_ref56","volume-title":"Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)"},{"key":"2021030800244033300_ref57","volume-title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)"},{"key":"2021030800244033300_ref58","volume-title":"Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)"},{"key":"2021030800244033300_ref59"},{"key":"2021030800244033300_ref60","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"2021030800244033300_ref61","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJM198611273152202","article-title":"Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung","volume":"315","author":"Lung Cancer Study Group","year":"1986","journal-title":"N Engl J Med"},{"key":"2021030800244033300_ref62","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/bjc.1996.413","article-title":"The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party","volume":"74","author":"Stephens","year":"1996","journal-title":"Br J Cancer"},{"key":"2021030800244033300_ref63","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(98)06341-7","article-title":"Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials","volume":"352","author":"PORT Meta-analysis Trialists Group","year":"1998","journal-title":"Lancet"},{"key":"2021030800244033300_ref64","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.lungcan.2014.02.016","article-title":"Evidence supporting contemporary post-operative radiation therapy (PORT) using linear accelerators in N2 lung cancer","volume":"84","author":"Patel","year":"2014","journal-title":"Lung Cancer"},{"key":"2021030800244033300_ref65","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in Resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"2021030800244033300_ref66","volume-title":"Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC"},{"key":"2021030800244033300_ref67","volume-title":"Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091\/KEYNOTE-091) (PEARLS)"},{"key":"2021030800244033300_ref68","volume-title":"Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL)"},{"key":"2021030800244033300_ref69","volume-title":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]"},{"key":"2021030800244033300_ref70","volume-title":"Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant\/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671\/KEYNOTE-671)"},{"key":"2021030800244033300_ref71","volume-title":"A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)"},{"key":"2021030800244033300_ref72","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.athoracsur.2018.02.030","article-title":"Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors","volume":"106","author":"Bott","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"2021030800244033300_ref73","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2019.37.15_suppl.8504","article-title":"Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): clinical and correlative results from the NEOSTAR study","volume":"37","author":"Cascone","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021030800244033300_ref74","doi-asserted-by":"crossref","DOI":"10.1111\/1759-7714.13697","article-title":"Cohesion between pulmonary artery and bronchus after immune checkpoint inhibitor therapy in a lung cancer patient","author":"Takamori","year":"2020","journal-title":"Thorac Cancer"},{"key":"2021030800244033300_ref75","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11864-019-0652-3","article-title":"When to consider immune checkpoint inhibitors in oncogene-driven non-small cell lung cancer?","volume":"20","author":"Mhanna","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"2021030800244033300_ref76","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1016\/j.jtho.2019.08.480","article-title":"OA13.05 NADIM study: updated clinical research and outcomes","volume":"14","author":"Provencio","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2021030800244033300_ref77","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","article-title":"Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data","volume":"14","author":"Mauguen","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021030800244033300_ref78","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cllc.2019.11.003","article-title":"Agreement on major pathological response in NSCLC patients receiving neoadjuvant chemotherapy","volume":"21","author":"Weissferdt","year":"2020","journal-title":"Clin Lung Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/3\/333\/36446348\/hyaa249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/3\/333\/36446348\/hyaa249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:25:53Z","timestamp":1615163153000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/51\/3\/333\/6121627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":78,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,1,28]]},"published-print":{"date-parts":[[2021,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa249","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2021,1,28]]}}}